This study suggests that HAT1 regulates the sensitivity of pancreatic cancer to gemcitabine by regulating PVT1/EZH2 complex, highlighting the importance of HAT1 in the development of gemcitabine resistance in pancreatic cancer. Here, PVT1 is linked to pancreatic neoplasm.